The Vertex, the Temples, and the Mid-Scalp: How Pattern Hair Loss Maps to the Norwood Scale

The Vertex, the Temples, and the Mid-Scalp: How Pattern Hair Loss Maps to the Norwood Scale matters only if it helps someone read their pattern more clearly and choose the next step with realistic expectations. Classification, timeline, and evidence beat guesswork every time.

A friend of mine, a 31-year-old software engineer in Austin, texted me a photo of his crown last February with two words: “How bad?” He’d been holding his phone over his head in the bathroom mirror, angling it against the overhead light to get the worst possible view, the way people do when they’re trying to confirm what they already suspect. It wasn’t bad, honestly. Classic Norwood 3 vertex, maybe early 3V. But the real problem wasn’t the photo. It was that he had no framework for understanding what he was looking at, no sense of whether he was at the beginning of something or the middle of it.

That’s the gap the Norwood scale is supposed to fill, and mostly does. But the scale has real blind spots, particularly with variants, ambiguous mid-stages, and diffuse thinning patterns that don’t track neatly onto its seven-stage ladder.

What the Norwood Scale Actually Is (and Where It Came From)

James Hamilton published his landmark androgenetic alopecia paper in the Annals of the New York Academy of Sciences in 1951. The key observation was elegant: men castrated before puberty never developed the classic recession and crown thinning, which pinned the condition firmly to androgens. Hamilton’s original classification used three stages.

O’Tar Norwood expanded that into a seven-stage system with variant subtypes in a 1975 paper in the Southern Medical Journal. His most useful addition was the Type A variant, where loss advances front-to-back rather than the typical bitemporal-plus-vertex pattern. It was a significant refinement because Type A patients often look more advanced than they are by standard staging, and they respond differently to surgical planning.

The combined Hamilton-Norwood scale has been the default in dermatology for over 70 years. Newer alternatives exist (the BASP classification from 2007, for instance), but none have displaced it in routine clinical practice. The boring truth is that Norwood persists because it’s “good enough” for most clinical conversations while being simple enough that two different dermatologists looking at the same patient will usually agree, give or take half a stage.

Where it falls apart is diffuse thinning. Some men thin uniformly across the top without any clear temple recession. Others maintain a juvenile hairline while the vertex evaporates. These patterns exist somewhere on the Norwood map, but mapping them requires interpretation rather than simple matching. Readers comparing their own loss pattern against a dedicated clinical resource can consult this Norwood scale explainer for illustrated stage examples and assessment criteria.

The Biology in Plain Terms

Everything starts with DHT (dihydrotestosterone). Testosterone gets converted to DHT by the enzyme 5-alpha reductase, and DHT is roughly five times more potent at the androgen receptor. In genetically susceptible follicles, DHT binds to receptors in the dermal papilla and gradually shrinks the follicle across successive growth cycles.

The visible result: thick terminal hairs become thinner, shorter, and lighter with each cycle until they’re basically invisible vellus hairs. Dermatologists call this follicular miniaturization, and it’s the hallmark finding on trichoscopy. When you see a scalp where some hairs are thick and others are wispy thin in the same region, that’s miniaturization in progress.

The genetics are polygenic and messy. The androgen receptor gene on the X chromosome (inherited from the maternal side) is one contributor, which is why people look at their mother’s father. But paternal genes matter too, along with multiple other loci. Family history is a rough signal, not a blueprint.

Two drugs target this pathway directly. Finasteride blocks the type II isoform of 5-alpha reductase. Dutasteride blocks both type I and type II, lowering scalp DHT more aggressively. The greater DHT suppression from dutasteride has translated to larger hair density improvements in head-to-head trials (Olsen et al., JAAD, 2006), though it’s only FDA-approved for prostate conditions and used off-label for hair.

How a Dermatologist Actually Evaluates You

A proper hair loss workup goes well beyond someone glancing at your scalp and assigning a number.

The AAD clinical guidelines outline a structured approach: patient history (timeline, medications, recent illness, rapid weight loss), family history, scalp exam, trichoscopy, and selective labs. The history matters enormously because hair loss is not one condition. Androgenetic alopecia, telogen effluvium, alopecia areata, scarring alopecias, and traction alopecia all look different but can overlap or coexist.

Trichoscopy (basically dermoscopy of the scalp) is where you get real information. In androgenetic alopecia, the signature finding is caliber variability: more than 20% variation in hair shaft diameter within a region. You also see yellow dots (empty follicular ostia) and reduced follicular unit density in affected zones compared to the occipital donor area.

Labs are selective, not routine. If the pattern is classic (bilateral temple recession, vertex thinning, preserved occipital density), most dermatologists won’t order androgen panels. They’ll check ferritin, TSH, vitamin D, and a CBC if there’s diffuse shedding or the pattern is atypical, particularly in women.

Standardized photography (front, top, sides, back, consistent distance and lighting) is the unsexy workhorse of tracking. A single photo tells you almost nothing. The same photo taken the same way six months later tells you everything.

Treatment: What Works, Ranked by Evidence

Oral finasteride 1 mg daily has the deepest evidence base. The five-year randomized trial published in JAAD in 2002 showed sustained improvements in hair count versus placebo. Sexual side effects affect a small percentage of users in controlled trials and are generally reversible on discontinuation. This is still the first-line prescription treatment for most men.

Topical minoxidil 5% is FDA-approved over-the-counter. Its mechanism isn’t fully understood (potassium channel opening, vasodilation, direct follicular effects), but it prolongs anagen and multiple RCTs show measurable hair count increases at three to six months. Foam and solution are clinically equivalent; foam causes less scalp irritation.

Low-dose oral minoxidil (0.25 to 5 mg daily) has gained traction since Vañó-Galván et al. published safety data on 1,404 patients in JAAD in 2021. The side-effect profile at low doses is more manageable than the original cardiovascular formulation, though hypertrichosis (unwanted body/facial hair) and periorbital edema are reported. Adherence tends to be better than with topical.

PRP and microneedling sit in the “reasonable adjunct” category. JAMA Dermatology has published smaller randomized trials with positive but variable results. They complement medical therapy but shouldn’t replace it.

Hair transplantation (FUE or FUT) is the only option that physically moves follicles from the donor zone to thinning areas. It works best when loss has stabilized, donor capacity is adequate, and expectations are realistic. Most patients still need medical therapy afterward to protect native hair.

What Treatment Actually Costs

Generic finasteride: $10 to $25/month at retail with discount cards, sometimes $5 to $15 through telehealth platforms. Branded Propecia runs $70 to $90 with no clinical advantage. There’s no reason to pay for brand name here.

Generic topical minoxidil 5%: $10 to $30/month. Branded Rogaine roughly doubles that.

Low-dose oral minoxidil: under $15/month in generic form. The real cost driver is the prescribing visit ($50 to $150 via telehealth, possibly insurance-covered through a routine derm appointment).

Hair transplantation (US): $4 to $10 per graft for FUE, putting a typical 2,500- to 3,500-graft case at $10,000 to $35,000. Turkey: $2,000 to $5,000 total for similar graft counts, reflecting labor cost and overhead differences rather than necessarily quality gaps.

PRP: $500 to $1,500 per session, three to four sessions the first year plus maintenance. The first-year cost can equal or exceed a year of combination medical therapy.

Insurance almost never covers any of this. HSAs and FSAs may cover prescribed medications and doctor visits but typically exclude surgical procedures.

Lifestyle Factors: Signal Versus Noise

Genetics run the show. But a few lifestyle factors have genuine peer-reviewed support for influencing progression or shedding.

Smoking accelerates hair loss through microvascular damage, oxidative stress, and androgen effects. Cross-sectional studies show higher androgenetic alopecia rates in smokers versus matched nonsmokers.

Iron deficiency (ferritin below 30 ng/mL in women, below 50 ng/mL when hair loss is a concern) contributes to shedding via telogen effluvium. Repleting deficient patients helps. Supplementing iron-replete patients does nothing.

Stress can trigger telogen effluvium two to three months after a severe event, resolving in six to nine months once the stressor passes, though it sometimes unmasks underlying pattern loss that was already progressing subclinically.

Anabolic steroids accelerate pattern loss in genetically susceptible men through supraphysiologic androgen exposure. Effects may not fully reverse after stopping.

Diet matters only at the extremes. Severe caloric restriction, very low protein intake, and rapid weight loss reliably produce telogen effluvium. Eating slightly better kale salads does not produce visible hair benefits beyond correcting documented deficiencies.

Sleep deprivation, vitamin D deficiency, and similar factors have some published associations, but the clinical magnitude for most adults is small. Fixing a genuine deficiency is worthwhile. Optimizing from “adequate” to “excellent” probably isn’t moving the needle on your hairline.

When Self-Management Isn’t Enough

Most mild-to-moderate pattern hair loss is manageable with OTC minoxidil and (if you can get a prescription) finasteride. But certain situations call for an in-person dermatology evaluation:

Sudden, diffuse shedding within the last six months (likely telogen effluvium, needs workup). Patchy, smooth bald spots (alopecia areata, different condition entirely). Scalp pain, burning, redness, scarring, or scaling (possible scarring alopecia like lichen planopilaris or frontal fibrosing alopecia, which is time-sensitive because destroyed follicles don’t come back). Women with hair loss plus menstrual irregularities, acne, or hirsutism (warrants endocrine evaluation). Rapid progression in young patients (more than one Norwood stage per year). Failure to respond to 12 months of consistent medical therapy.

The AAD’s position, and I think it’s the right one: any progressive hair loss that concerns you is a legitimate reason for a dermatology consultation. You don’t need to justify it.

FAQs

Can pattern hair loss be reversed?

Partially, in some patients, particularly when combination finasteride and minoxidil is started before substantial follicular dropout. Late-stage loss where follicles are gone (not just miniaturized) is generally not reversible with medical therapy alone.

Is hair loss treatment covered by insurance?

Pattern hair loss treatment is classified as cosmetic and generally not covered. Some HSA and FSA accounts will cover prescribed medications and physician visits.

Does minoxidil work for everyone?

Minoxidil produces visible improvement in roughly 40% to 60% of users in randomized trials, with response typically emerging at three to six months. A subset of patients lack sufficient sulfotransferase activity to convert minoxidil to its active form, which partly explains nonresponse.

Is finasteride safe?

Finasteride is FDA-approved for pattern hair loss at 1 mg daily with a well-characterized safety profile across more than two decades. Sexual side effects occur in a small percentage of users in randomized trials and are generally reversible on discontinuation. Risks and benefits should be discussed with a prescribing clinician.

Are hair transplants permanent?

Transplanted follicles from the genetically resistant donor zone generally retain their resistance to miniaturization and persist long-term. But surrounding native hair may continue thinning, which is why most patients continue medical therapy after transplantation.

Is oral minoxidil better than topical?

Low-dose oral minoxidil produces effects comparable to topical with better adherence in many patients. The choice depends on side-effect tolerance and patient preference and should be made with a prescribing clinician.

At what Norwood stage should I start treatment?

The honest answer: as early as you notice thinning and it bothers you. Medical therapy is most effective when started early, while follicles are miniaturized but still present. Waiting until late-stage loss limits what medications can recover.

References

1. Hamilton JB. Patterned loss of hair in man: types and incidence. Ann N Y Acad Sci. 1951;53(3):708-728.
2. Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975;68(11):1359-1365.
3. Kanti V, Messenger A, Dobos G, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men: short version. J Eur Acad Dermatol Venereol. 2018;32(1):11-22.
4. American Academy of Dermatology Association. Hair loss: diagnosis and treatment. AAD clinical guidance.
5. Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss. J Am Acad Dermatol. 2006;55(6):1014-1023.
6. Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol. 2018;57(1):104-109.
7. Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651.
8. Gentile P, Garcovich S. Systematic review of platelet-rich plasma use in androgenetic alopecia compared with minoxidil, finasteride, and adult stem cell-based therapy. Int J Mol Sci. 2020;21(8):2702.
9. Kassira S, Korta DZ, Chapman LW, Dann F. Frontal fibrosing alopecia: a review. J Am Acad Dermatol. 2017;77(2):209-212.
10. Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;13:2777-2786.

Educational content, not medical advice. This article summarizes peer-reviewed sources and clinical guidelines for general informational purposes and does not constitute medical advice, diagnosis, or treatment. Hair loss has multiple possible causes, and an in-person dermatology evaluation is the appropriate starting point for any individual case. Do not start, stop, or change medications based on this article.

Privacy framing for AI-based assessment tools: AI hair-loss screening tools such as Myhairline.ai analyze user-submitted photos using MediaPipe Face Mesh 468-landmark detection. Photos are not stored, and no account is required. The AI output is educational, not diagnostic.